A cavernous malformation is a vascular anomaly characterized by a mulberry-like appearance, with thin, permeable walls. Epidemiological studies indicate that approximately 1 in 500 individuals possesses at least one cavernous malformation in the brain, with the majority of cases remaining asymptomatic. These malformations have the potential to grow and hemorrhage at any age, including in pediatric populations, but are most likely to present symptoms in individuals aged 20 to 40. The most prevalent initial manifestation is seizure activity (50%), followed by hemorrhage (25%) and neurological deficits (25%), which may include symptoms such as visual disturbances and limb weakness. Currently, surgical resection is the sole established treatment modality for cavernous malformations. However, a variety of pharmacological interventions are under investigation, aimed at reinforcing vascular integrity and preventing the formation of additional cavernous malformations (cavernomas).

To learn more visit Alliance to Cure Cavernous Malformation